Biosimilar medicines in oncology: Single-center experience with biosimilar G-CSF

Future Oncology

Volumn 8, Issue 5, 2012, Pages 625-630

  Salesi, Nello ^a   Di Cocco, Barbara ^a   Colonna, Maria ^a   Veltri, Enzo ^a  

^a Lazio Local Health Authority ^*  (Italy)

Author keywords

biosimilars; febrile neutropenia; filgrastim; granulocyte colony stimulating factor

Indexed keywords

AMIKACIN; BIOLOGICAL PRODUCT; BIOSIMILAR AGENT; CAPECITABINE; CEFTAZIDIME; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; EP 2006; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; OXALIPLATIN; PLATINUM DERIVATIVE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG; XM 02;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BONE METASTASIS; BREAST CANCER; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONTINUOUS INFUSION; COST CONTROL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HOSPITALIZATION; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG CARCINOMA; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OBSERVATIONAL STUDY; PATENT; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; RISK REDUCTION; SECOND CANCER; SINGLE DRUG DOSE; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; STOMACH ADENOCARCINOMA; STOMACH CANCER; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOSIMILAR PHARMACEUTICALS; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; TREATMENT OUTCOME;

EID: 84861729704     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.12.32     Document Type: Article

References (8)

1. Aapro MS, Bohlius J, Cameron DA et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur. J. Cancer 47(1), 8-32 (2011).
2. Ozer H, Armitage JO, Bennett CL et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J. Clin. Oncol. 18(20), 3558-3585 (2000).
3. European Medicines Agency. CHMP/437/04 - Guideline on Similar Biological Medicinal Products. London, UK (2005).
4. European Medicines Agency. EMEA/CHMP/ BWP/49348/2005 - Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues. London, UK (2006).
5. European Public Assessment Report. EMEA/ CHMP/BMWP/31329/2005 - Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: Non-clinical and clinical issues guidance on similar medicinal products containing recombinant granulocyte-colony stimulating factor. London, UK (2006).
6. European Medicines Agency. EMEA/ CHMP/651339/2008 - CHMP Assessment Report for Zarzio. London, UK (2008).
7. Gascon P, Fuhr U, Sörgel F et al. Development of a new G-CSF product based on biosimilarity assessment. Ann. Oncol. 21, 1419-1429 (2010).
8. Aapro M, Cornes P, Abraham I. Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia. J. Oncol. Pharm. Pract. doi: 10.1177/1078155211407367 (2011) (Epub ahead of print).